Oncogene, ISSN 0950-9232, 03/2015, Volume 34, Issue 11, pp. 1442 - 1450
Serine threonine kinase AKT has a central role in the cell, controlling survival, proliferation, metabolism and angiogenesis. Deregulation of its activity...
ACTIVATION | QUANTITATIVE PROTEOMICS | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | HEAT-SHOCK | ONCOGENIC TRANSFORMATION | SUMO-1 MODIFICATION | PROTEIN-KINASE B | PML | CELL BIOLOGY | ONCOLOGY | PATHWAY | GENETICS & HEREDITY | NIH3T3 CELLS | Phosphorylation | Cell Proliferation | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Cercopithecus aethiops | Apoptosis - genetics | Sumoylation - physiology | Proto-Oncogene Proteins c-akt - genetics | MCF-7 Cells | HEK293 Cells | Female | Proto-Oncogene Proteins c-akt - metabolism | Ubiquitins - metabolism | Sumoylation - genetics | Signal Transduction | Small Ubiquitin-Related Modifier Proteins - metabolism | Animals | Cell Line, Tumor | Mice | SUMO-1 Protein - metabolism | Enzyme Activation | HeLa Cells | Mutation | Neoplasms - pathology | COS Cells | 3T3 Cells | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Ubiquitin | Cell proliferation | Analysis | Physiological aspects | Genetic aspects | Research | Protein kinases | Angiogenesis | Kinases | Metabolism | Cancer
ACTIVATION | QUANTITATIVE PROTEOMICS | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | HEAT-SHOCK | ONCOGENIC TRANSFORMATION | SUMO-1 MODIFICATION | PROTEIN-KINASE B | PML | CELL BIOLOGY | ONCOLOGY | PATHWAY | GENETICS & HEREDITY | NIH3T3 CELLS | Phosphorylation | Cell Proliferation | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Cercopithecus aethiops | Apoptosis - genetics | Sumoylation - physiology | Proto-Oncogene Proteins c-akt - genetics | MCF-7 Cells | HEK293 Cells | Female | Proto-Oncogene Proteins c-akt - metabolism | Ubiquitins - metabolism | Sumoylation - genetics | Signal Transduction | Small Ubiquitin-Related Modifier Proteins - metabolism | Animals | Cell Line, Tumor | Mice | SUMO-1 Protein - metabolism | Enzyme Activation | HeLa Cells | Mutation | Neoplasms - pathology | COS Cells | 3T3 Cells | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Ubiquitin | Cell proliferation | Analysis | Physiological aspects | Genetic aspects | Research | Protein kinases | Angiogenesis | Kinases | Metabolism | Cancer
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 04/2012, Volume 122, Issue 4, pp. 1519 - 1528
Genetic mutations that give rise to active mutant forms of Ras are oncogenic and found in several types of tumor. However, such mutations are not clear...
SIGNAL-TRANSDUCTION | PROTEASE INHIBITOR | MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC DUCTAL ADENOCARCINOMA | ACTIVATION | K-RAS | ONCOGENIC KRAS | MOUSE MODEL | IN-VIVO | ACINAR-CELLS | CANCER | Inflammation - chemically induced | Pancreatic Neoplasms - metabolism | Pancreatic Neoplasms - etiology | Humans | Carcinoma, Pancreatic Ductal - metabolism | Sincalide - toxicity | Pancreatitis, Chronic - chemically induced | Proto-Oncogene Proteins p21(ras) - physiology | Gabexate - toxicity | I-kappa B Kinase - physiology | Carcinoma, Pancreatic Ductal - genetics | Cyclooxygenase 2 - biosynthesis | Inflammation - complications | Inflammation - metabolism | Cell Transformation, Neoplastic - genetics | Inflammation Mediators - metabolism | Carcinoma, Pancreatic Ductal - etiology | Gene Expression Regulation, Neoplastic - physiology | I-kappa B Kinase - deficiency | Lipopolysaccharides - toxicity | Cyclooxygenase 2 Inhibitors - pharmacology | Neoplasm Proteins - biosynthesis | Pancreatic Neoplasms - pathology | Ceruletide - toxicity | Enzyme Induction | Cyclooxygenase 2 - physiology | Gabexate - analogs & derivatives | Mice, Transgenic | Pancreatic Neoplasms - genetics | I-kappa B Kinase - genetics | Pancreas - metabolism | Pancreatitis, Chronic - genetics | Carcinoma, Pancreatic Ductal - pathology | Precancerous Conditions - genetics | Proto-Oncogene Proteins p21(ras) - biosynthesis | Gene Knock-In Techniques | Animals | NF-kappa B - physiology | Inflammation - genetics | Mice | Feedback, Physiological - physiology | Precancerous Conditions - chemically induced | Genes, ras | Pancreatitis, Chronic - metabolism
SIGNAL-TRANSDUCTION | PROTEASE INHIBITOR | MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC DUCTAL ADENOCARCINOMA | ACTIVATION | K-RAS | ONCOGENIC KRAS | MOUSE MODEL | IN-VIVO | ACINAR-CELLS | CANCER | Inflammation - chemically induced | Pancreatic Neoplasms - metabolism | Pancreatic Neoplasms - etiology | Humans | Carcinoma, Pancreatic Ductal - metabolism | Sincalide - toxicity | Pancreatitis, Chronic - chemically induced | Proto-Oncogene Proteins p21(ras) - physiology | Gabexate - toxicity | I-kappa B Kinase - physiology | Carcinoma, Pancreatic Ductal - genetics | Cyclooxygenase 2 - biosynthesis | Inflammation - complications | Inflammation - metabolism | Cell Transformation, Neoplastic - genetics | Inflammation Mediators - metabolism | Carcinoma, Pancreatic Ductal - etiology | Gene Expression Regulation, Neoplastic - physiology | I-kappa B Kinase - deficiency | Lipopolysaccharides - toxicity | Cyclooxygenase 2 Inhibitors - pharmacology | Neoplasm Proteins - biosynthesis | Pancreatic Neoplasms - pathology | Ceruletide - toxicity | Enzyme Induction | Cyclooxygenase 2 - physiology | Gabexate - analogs & derivatives | Mice, Transgenic | Pancreatic Neoplasms - genetics | I-kappa B Kinase - genetics | Pancreas - metabolism | Pancreatitis, Chronic - genetics | Carcinoma, Pancreatic Ductal - pathology | Precancerous Conditions - genetics | Proto-Oncogene Proteins p21(ras) - biosynthesis | Gene Knock-In Techniques | Animals | NF-kappa B - physiology | Inflammation - genetics | Mice | Feedback, Physiological - physiology | Precancerous Conditions - chemically induced | Genes, ras | Pancreatitis, Chronic - metabolism
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2008, Volume 14, Issue 1, pp. 240 - 248
Purpose: The heat shock protein 90 (Hsp90) chaperone plays an important role in transformation by regulating the conformational maturation and stability of...
HSP90 | breast cancer | 17-AAG | Geldanamycin | HER2 | HSP90 INHIBITORS | PROTEIN | ANSAMYCINS | ONCOLOGY | PHASE-I TRIAL | GELDANAMYCIN | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN | GROWTH-FACTOR RECEPTORS | DEGRADATION | ONCOGENIC TRANSFORMATION | B-RAF | Extracellular Signal-Regulated MAP Kinases - drug effects | Humans | Immunoblotting | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacokinetics | Benzoquinones - pharmacology | Xenograft Model Antitumor Assays | Animals | Lactams, Macrocyclic - pharmacokinetics | Prodrugs - pharmacokinetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Mice, Nude | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Receptor, ErbB-2 - drug effects | Neoplasms, Experimental - drug therapy | Prodrugs - pharmacology
HSP90 | breast cancer | 17-AAG | Geldanamycin | HER2 | HSP90 INHIBITORS | PROTEIN | ANSAMYCINS | ONCOLOGY | PHASE-I TRIAL | GELDANAMYCIN | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN | GROWTH-FACTOR RECEPTORS | DEGRADATION | ONCOGENIC TRANSFORMATION | B-RAF | Extracellular Signal-Regulated MAP Kinases - drug effects | Humans | Immunoblotting | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacokinetics | Benzoquinones - pharmacology | Xenograft Model Antitumor Assays | Animals | Lactams, Macrocyclic - pharmacokinetics | Prodrugs - pharmacokinetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Mice, Nude | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Receptor, ErbB-2 - drug effects | Neoplasms, Experimental - drug therapy | Prodrugs - pharmacology
Journal Article
Cancer Cell, ISSN 1535-6108, 03/2017, Volume 31, Issue 3, pp. 311 - 325
T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling pathways in tumor cells help produce a suppressive tumor...
adoptive T cell therapy | tumor microenvironment | TME | T cell dysfunction | genetic engineering | immunotherapy | INTERLEUKIN-8 EXPRESSION | ONCOLOGY | ONCOGENIC KRAS | INDOLEAMINE 2,3-DIOXYGENASE | RECEPTOR EXPRESSION | FATTY-ACID SYNTHASE | FOCAL ADHESION KINASE | PROGNOSTIC-SIGNIFICANCE | ANTITUMOR-ACTIVITY | WNT/BETA-CATENIN PATHWAY | HUMAN PANCREATIC-CANCER | CELL BIOLOGY | Neoplasms - metabolism | Humans | Lactic Acid - metabolism | Tumor Microenvironment | Receptors, Antigen, T-Cell - physiology | Amino Acids - metabolism | Genes, p53 | Neoplasms - therapy | Neoplasms - immunology | Glucose - metabolism | T-Lymphocytes - immunology | Fatty Acids - metabolism | Cytotoxicity, Immunologic | Medical colleges | Antigens | Melanoma | Development and progression | T cells | Cancer | Ovarian cancer | Medical research | Immunotherapy | Medicine, Experimental
adoptive T cell therapy | tumor microenvironment | TME | T cell dysfunction | genetic engineering | immunotherapy | INTERLEUKIN-8 EXPRESSION | ONCOLOGY | ONCOGENIC KRAS | INDOLEAMINE 2,3-DIOXYGENASE | RECEPTOR EXPRESSION | FATTY-ACID SYNTHASE | FOCAL ADHESION KINASE | PROGNOSTIC-SIGNIFICANCE | ANTITUMOR-ACTIVITY | WNT/BETA-CATENIN PATHWAY | HUMAN PANCREATIC-CANCER | CELL BIOLOGY | Neoplasms - metabolism | Humans | Lactic Acid - metabolism | Tumor Microenvironment | Receptors, Antigen, T-Cell - physiology | Amino Acids - metabolism | Genes, p53 | Neoplasms - therapy | Neoplasms - immunology | Glucose - metabolism | T-Lymphocytes - immunology | Fatty Acids - metabolism | Cytotoxicity, Immunologic | Medical colleges | Antigens | Melanoma | Development and progression | T cells | Cancer | Ovarian cancer | Medical research | Immunotherapy | Medicine, Experimental
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2010, Volume 149, Issue 4, pp. 537 - 549
Summary This study investigated the cytotoxicity and mechanism of action of AS703026, a novel, selective, orally bioavailable MEK1/2 inhibitor, in human...
bone marrow stromal cells (BMSCs) | novel kinase inhibitor therapy | multiple myeloma (MM) | MEK1/2 inhibitor | Bone marrow stromal cells (BMSCs) | Novel kinase inhibitor therapy | Multiple myeloma (MM) | GENE-MUTATIONS | N-RAS | BONE-MARROW | 2 inhibitor | BRAF GENE | ACTIVATING RAS MUTATIONS | PROTEIN-KINASE CASCADE | ONCOGENIC RAS | VEGF SECRETION | MEK1 | PLASMA-CELL LEUKEMIA | HEMATOLOGY | HUMAN MULTIPLE-MYELOMA | Niacinamide - analogs & derivatives | MAP Kinase Kinase 1 - antagonists & inhibitors | Apoptosis - drug effects | Humans | Niacinamide - therapeutic use | Mice, SCID | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Xenograft Model Antitumor Assays | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | MAP Kinase Signaling System - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Cell Death - drug effects | Niacinamide - pharmacology | Tumor Cells, Cultured | Cell research | Dexamethasone | Sugars | Multiple myeloma | Tumors | Monosaccharides
bone marrow stromal cells (BMSCs) | novel kinase inhibitor therapy | multiple myeloma (MM) | MEK1/2 inhibitor | Bone marrow stromal cells (BMSCs) | Novel kinase inhibitor therapy | Multiple myeloma (MM) | GENE-MUTATIONS | N-RAS | BONE-MARROW | 2 inhibitor | BRAF GENE | ACTIVATING RAS MUTATIONS | PROTEIN-KINASE CASCADE | ONCOGENIC RAS | VEGF SECRETION | MEK1 | PLASMA-CELL LEUKEMIA | HEMATOLOGY | HUMAN MULTIPLE-MYELOMA | Niacinamide - analogs & derivatives | MAP Kinase Kinase 1 - antagonists & inhibitors | Apoptosis - drug effects | Humans | Niacinamide - therapeutic use | Mice, SCID | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Xenograft Model Antitumor Assays | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | MAP Kinase Signaling System - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Cell Death - drug effects | Niacinamide - pharmacology | Tumor Cells, Cultured | Cell research | Dexamethasone | Sugars | Multiple myeloma | Tumors | Monosaccharides
Journal Article
Oncogene, ISSN 0950-9232, 03/2013, Volume 32, Issue 13, pp. 1616 - 1625
HOTAIR is a long intervening non-coding RNA (lincRNA) that associates with the Polycomb Repressive Complex 2 (PRC2) and overexpression is correlated with poor...
HOTAIR | Cell cycle progression | Pro-oncogenic | Invasion | Prognostic | ACTIVATION | pro-oncogenic | PROTEIN | CHROMATIN | DUCTAL ADENOCARCINOMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | MECHANISMS | CELL BIOLOGY | prognostic | INTERFERON | invasion | LONG NONCODING RNA | REPRESSION | ONCOLOGY | GENETICS & HEREDITY | GENE-EXPRESSION | cell cycle progression | MIRNAS | Prognosis | Pancreatic Neoplasms - diagnosis | Humans | Transplantation, Heterologous | RNA, Long Noncoding - physiology | Carcinoma, Pancreatic Ductal - genetics | Gene Knockdown Techniques | Cell Transformation, Neoplastic - genetics | Biomarkers, Tumor - metabolism | Carcinoma, Pancreatic Ductal - diagnosis | Female | Gene Expression Regulation, Neoplastic - drug effects | Gene Expression Regulation, Neoplastic - physiology | Pancreatic Neoplasms - pathology | RNA, Small Interfering - pharmacology | Pancreatic Neoplasms - genetics | Biomarkers, Tumor - physiology | RNA, Long Noncoding - genetics | Carcinoma, Pancreatic Ductal - pathology | Animals | Cell Line, Tumor | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Cell Transformation, Neoplastic - drug effects | RNA, Long Noncoding - antagonists & inhibitors | RNA, Long Noncoding - metabolism | RNA | Pancreatic cancer | Physiological aspects | Genetic aspects | Research | Gene expression | Oncology | Cell cycle | Tumors
HOTAIR | Cell cycle progression | Pro-oncogenic | Invasion | Prognostic | ACTIVATION | pro-oncogenic | PROTEIN | CHROMATIN | DUCTAL ADENOCARCINOMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | MECHANISMS | CELL BIOLOGY | prognostic | INTERFERON | invasion | LONG NONCODING RNA | REPRESSION | ONCOLOGY | GENETICS & HEREDITY | GENE-EXPRESSION | cell cycle progression | MIRNAS | Prognosis | Pancreatic Neoplasms - diagnosis | Humans | Transplantation, Heterologous | RNA, Long Noncoding - physiology | Carcinoma, Pancreatic Ductal - genetics | Gene Knockdown Techniques | Cell Transformation, Neoplastic - genetics | Biomarkers, Tumor - metabolism | Carcinoma, Pancreatic Ductal - diagnosis | Female | Gene Expression Regulation, Neoplastic - drug effects | Gene Expression Regulation, Neoplastic - physiology | Pancreatic Neoplasms - pathology | RNA, Small Interfering - pharmacology | Pancreatic Neoplasms - genetics | Biomarkers, Tumor - physiology | RNA, Long Noncoding - genetics | Carcinoma, Pancreatic Ductal - pathology | Animals | Cell Line, Tumor | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Cell Transformation, Neoplastic - drug effects | RNA, Long Noncoding - antagonists & inhibitors | RNA, Long Noncoding - metabolism | RNA | Pancreatic cancer | Physiological aspects | Genetic aspects | Research | Gene expression | Oncology | Cell cycle | Tumors
Journal Article
The EMBO Journal, ISSN 0261-4189, 07/2007, Volume 26, Issue 14, pp. 3332 - 3345
The c‐Myc oncoprotein promotes cell growth by enhancing ribosomal biogenesis through upregulation of RNA polymerases I‐, II‐, and III‐dependent transcription....
ribosomal proteins | transcription | cell cycle | TRRAP | L11 | C‐Myc | C-Myc | Ribosomal proteins | Transcription | Cell cycle | MYC/MAX/MAD NETWORK | RNA-POLYMERASE-I | TRANSCRIPTIONAL ACTIVATION | c-Myc | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-SIZE | ONCOGENIC TRANSFORMATION | P53 | CELL BIOLOGY | ESSENTIAL COFACTOR | PATHWAY | GENES | DEGRADATION | Ribosomal Proteins - chemistry | RNA-Binding Proteins - genetics | Transcriptional Activation - genetics | Cell Proliferation | Humans | Phosphoproteins - metabolism | Promoter Regions, Genetic - genetics | Ribosomal Proteins - metabolism | S Phase | Serum | Transcription, Genetic | Acetylation | Protein Structure, Tertiary | Cell Line | Gene Expression | Ribosomal Proteins - genetics | Nuclear Proteins - metabolism | Phosphoproteins - genetics | Animals | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Protein Binding | Mice | Proto-Oncogene Proteins c-myc - genetics | Histones - metabolism | Adaptor Proteins, Signal Transducing - metabolism | Proto-Oncogene Proteins c-myc - chemistry | RNA-Binding Proteins - metabolism | RNA, Small Interfering - metabolism | Proteins | Inhibitor drugs | Cellular biology | Molecular biology | Gene expression
ribosomal proteins | transcription | cell cycle | TRRAP | L11 | C‐Myc | C-Myc | Ribosomal proteins | Transcription | Cell cycle | MYC/MAX/MAD NETWORK | RNA-POLYMERASE-I | TRANSCRIPTIONAL ACTIVATION | c-Myc | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-SIZE | ONCOGENIC TRANSFORMATION | P53 | CELL BIOLOGY | ESSENTIAL COFACTOR | PATHWAY | GENES | DEGRADATION | Ribosomal Proteins - chemistry | RNA-Binding Proteins - genetics | Transcriptional Activation - genetics | Cell Proliferation | Humans | Phosphoproteins - metabolism | Promoter Regions, Genetic - genetics | Ribosomal Proteins - metabolism | S Phase | Serum | Transcription, Genetic | Acetylation | Protein Structure, Tertiary | Cell Line | Gene Expression | Ribosomal Proteins - genetics | Nuclear Proteins - metabolism | Phosphoproteins - genetics | Animals | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Protein Binding | Mice | Proto-Oncogene Proteins c-myc - genetics | Histones - metabolism | Adaptor Proteins, Signal Transducing - metabolism | Proto-Oncogene Proteins c-myc - chemistry | RNA-Binding Proteins - metabolism | RNA, Small Interfering - metabolism | Proteins | Inhibitor drugs | Cellular biology | Molecular biology | Gene expression
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 11/2015, Volume 54, Issue 46, pp. 13516 - 13537
Small GTPases are a family of GDP‐/GTP‐binding proteins that serve as biomolecular switches inside cells to control a variety of essential cellular processes....
inhibitors | cancer | drug design | proteins | small GTPases | ONCOGENIC K-RAS | GUANINE-NUCLEOTIDE-EXCHANGE | HUMAN CANCER-CELLS | TOXIN-CATALYZED GLUCOSYLATION | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | SMALL-MOLECULE INHIBITORS | RHO FAMILY GTPASES | PROTEIN-PROTEIN INTERACTIONS | SPINAL-CORD-INJURY | RAS-EFFECTOR INTERACTIONS | Monomeric GTP-Binding Proteins - metabolism | Humans | Physiological aspects | Drug discovery | G proteins | Binding proteins | Gross domestic product | Protein binding | Proteins | Poverty | Drugs | Cellular | Modulation | Switches | Strategy | Holes | Modulators
inhibitors | cancer | drug design | proteins | small GTPases | ONCOGENIC K-RAS | GUANINE-NUCLEOTIDE-EXCHANGE | HUMAN CANCER-CELLS | TOXIN-CATALYZED GLUCOSYLATION | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | SMALL-MOLECULE INHIBITORS | RHO FAMILY GTPASES | PROTEIN-PROTEIN INTERACTIONS | SPINAL-CORD-INJURY | RAS-EFFECTOR INTERACTIONS | Monomeric GTP-Binding Proteins - metabolism | Humans | Physiological aspects | Drug discovery | G proteins | Binding proteins | Gross domestic product | Protein binding | Proteins | Poverty | Drugs | Cellular | Modulation | Switches | Strategy | Holes | Modulators
Journal Article
Gastroenterology, ISSN 0016-5085, 2009, Volume 137, Issue 3, pp. 1072 - 1082.e6
Background & Aims Differentiated pancreatic acinar cells expressing endogenous levels of mutant K-Ras do not spontaneously develop pancreatic ductal...
Gastroenterology and Hepatology | ACTIVATION | K-RAS | ONCOGENIC KRAS | MOUSE | ADULT MICE | INTRAEPITHELIAL NEOPLASIA | DUCTAL ADENOCARCINORNA | GASTROENTEROLOGY & HEPATOLOGY | CANCER | PROGRESSION | TRANSGENIC MICE | Pancreatic Neoplasms - metabolism | Humans | Pancreatic Neoplasms - pathology | Carcinoma, Pancreatic Ductal - metabolism | Mice, Transgenic | Pancreatic Neoplasms - genetics | Pancreatitis, Chronic - genetics | Carcinoma, Pancreatic Ductal - pathology | Carcinoma, Pancreatic Ductal - genetics | Pancreatitis, Chronic - pathology | Genes, ras - physiology | Animals | Cell Line, Tumor | Mice | Mutation | Pancreatitis, Chronic - metabolism | Genes, ras - genetics | Fluorescence | Development and progression | Transforming growth factors | Pancreatitis
Gastroenterology and Hepatology | ACTIVATION | K-RAS | ONCOGENIC KRAS | MOUSE | ADULT MICE | INTRAEPITHELIAL NEOPLASIA | DUCTAL ADENOCARCINORNA | GASTROENTEROLOGY & HEPATOLOGY | CANCER | PROGRESSION | TRANSGENIC MICE | Pancreatic Neoplasms - metabolism | Humans | Pancreatic Neoplasms - pathology | Carcinoma, Pancreatic Ductal - metabolism | Mice, Transgenic | Pancreatic Neoplasms - genetics | Pancreatitis, Chronic - genetics | Carcinoma, Pancreatic Ductal - pathology | Carcinoma, Pancreatic Ductal - genetics | Pancreatitis, Chronic - pathology | Genes, ras - physiology | Animals | Cell Line, Tumor | Mice | Mutation | Pancreatitis, Chronic - metabolism | Genes, ras - genetics | Fluorescence | Development and progression | Transforming growth factors | Pancreatitis
Journal Article